DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Pfeiffer syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePfeiffer syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pfeiffer syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
MDM4 regulator of p53 (MDM4) — MDM4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6Q9Y · 1.2 Å · ligand 7-methoxy-~{N}-[(3~{S})-1-(4-methylphenyl)pyrrolidin-3-yl]-1~{H}-indole-3-carboxamide (HRQ). Experimental structure, not a prediction.
What the evidence adds up to
A female infant with Pfeiffer syndrome is described in 1981; her mother has no limb malformations but shows craniofacial features that strongly suggest she is also affected, though more mildly. This family indicates that wide intrafamilial variation of Pfeiffer syndrome is possible and that without detailed investigation mildly affected subjects can remain undiagnosed, which may lead to erroneous genetic counselling.
Pfeiffer syndrome is a rare autosomal dominant disorder with an incidence of approximately 1:100,000 live births, characterised by coronal craniosynostosis, brachycephaly, mid-facial hypoplasia, and broad and deviated thumbs and great toes. A 2010 case describes a patient with a novel c833_834GC>TG mutation (encoding Cys278Leu) in the FGFR2 gene, associated with a coccygeal anomaly, which is rare in Pfeiffer syndrome. Mutations in FGFR1 or FGFR2 can cause the condition.
A 2021 case report describes an infant hospitalised in the Lviv Regional Clinical Hospital with multiple congenital malformations and severe neurological status. The phenotype included cloverleaf-shaped skull, broad thumbs and big toes, bilateral syndactyly, hypertelorism, acrocephaly, and severe concomitant neurological complications. The diagnosis of Pfeiffer syndrome was later confirmed.
No drug treatment, clinical trial, or survival data appear in any of these abstracts. What is missing is any investigation of pharmacological intervention, any systematic collection of outcomes beyond single case descriptions, and any patient stratification by mutation type or severity. No funding for therapeutic development or prospective natural-history studies is reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 1981 · 15 citations · open access
Variable expression in Pfeiffer syndrome.
AbstractA female infant with Pfeiffer syndrome (acrocephalosyndactyly V) is presented. Her mother has no limb malformations, but has craniofacial features with strongly suggest that she is also affected, although more mildly. This family indicates that wide intrafamilial variation of Pfeiffer syndrome is possible and suggests that without detailed investigation mildly affected subjects can remain undiagnosed, which may lead to erroneous genetic counselling.
Korean Journal of Pediatrics · 2010 · 11 citations · open access
A case of Pfeiffer syndrome with c833_834GC>TG (Cys278Leu) mutation in the<i>FGFR2</i>gene
AbstractPfeiffer syndrome is a rare autosomal dominant disorder characterized by coronal craniosynostosis, brachycephaly, mid-facial hypoplasia, and broad and deviated thumbs and great toes. Pfeiffer syndrome occurs in approximately 1:100,000 live births. Clinical manifestations and molecular genetic testing are important to confirm the diagnosis. Mutations of the fibroblast growth factor receptor 1 (FGFR1) gene or FGFR2 gene can cause Pfeiffer syndrome. Here, we describe a case of Pfeiffer syndrome with a novel c833_834GC>TG mutation (encoding Cys278Leu) in the FGFR2 gene associated with a coccygeal anomaly, which is rare in Pfeiffer syndrome.
Pediatria i Medycyna Rodzinna · 2021 · 0 citations · open access
Pfeiffer syndrome – a case report
AbstractPfeiffer syndrome is a severe autosomal dominant condition that affects many systems of the human body. It is caused by mutations in the fibroblast growth factor receptors of the fibroblast growth factor genes. The phenotype of patients with Pfeiffer syndrome includes multiple limb and cranial abnormalities, and mental retardation. The infant reported here also had cloverleaf-shaped skull, broad thumbs and big toes, bilateral syndactyly, and hypertelorism. The patient was hospitalised in the Lviv Regional Clinical Hospital with multiple congenital malformations and severe neurological status. Acrocephaly, cloverleaf-shaped skull and severe concomitant neurological complications suggested Pfeiffer syndrome, which was later confirmed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
